- Trial phase
- Approved (marketed device)
- Time to market
- Already marketed in China for GBM. The pancreatic cancer indication is under NMPA review (Innovative Medical Device Designation granted August 2025; submission planned H2 2025), with no confirmed approval date yet.
- Why 4/10
- OPTUNE is already approved and commercialized in China for GBM with no pending binary regulatory decision for that indication. The next potential catalyst is NMPA approval for pancreatic cancer, but no confirmed PDUFA or decision date exists as of November 2026. The drug is one of many products in Zai Lab's portfolio and its revenue is declining due to competition. Per the rubric, an approved marketed drug with no imminent new regulatory decision scores 3-5.
Watch for NMPA acceptance and a potential approval decision for OPTUNE in pancreatic cancer, which would open a large new addressable market in China. However, the lack of a confirmed submission or decision date as of Q3 2026 earnings means this catalyst is not imminent. Monitor quarterly revenue trends for Optune in GBM, as competition is eroding market share. Zai Lab's next major near-term catalyst is the November 30, 2026 PDUFA date for povetacicept in IgA nephropathy, a separate pipeline asset.
Price Chart
Executive Summary
OPTUNE (Tumor Treating Fields / TTFields) is a wearable medical device that uses electric fields to disrupt cancer cell division, developed by Novocure (NVCR) and exclusively licensed to Zai Lab (ZLAB) for Greater China. It is already approved and marketed in China for glioblastoma (GBM) since May 2020. Zai Lab is pursuing NMPA approval for a second indication in pancreatic cancer, having received Innovative Medical Device Designation in August 2025 based on positive Phase 3 PANOVA-3 data. However, Optune revenue is declining due to increasing competition in the GBM market, and the pancreatic cancer regulatory timeline remains unconfirmed. Optune is one of many products in Zai Lab's diversified portfolio, which includes ZEJULA, NUZYRA, VYVGART, KarXT, and a pipeline centered on the zoci ADC program.
How It Works
OPTUNE is a wearable, portable medical device that delivers low-intensity alternating electric fields (called Tumor Treating Fields or TTFields) through adhesive patches placed on the skin. These electric fields physically disrupt cancer cell division and can kill cancer cells without the systemic side effects of chemotherapy. It is not a drug or radiation therapy; it is a non-invasive physical treatment the patient wears for most of the day.
Trial Status
OPTUNE is already approved and marketed in China (NMPA approval May 2020) for newly diagnosed glioblastoma (GBM) in combination with temozolomide and as a monotherapy for recurrent GBM. It is also FDA-approved in the US for GBM and, since February 2026, for locally advanced pancreatic cancer (as Optune Pax). In China, Zai Lab received Innovative Medical Device Designation from the NMPA in August 2025 for the pancreatic cancer indication based on positive Phase 3 PANOVA-3 data, with a regulatory submission planned for the second half of 2025. The Phase 3 METIS trial also showed TTFields significantly delayed intracranial progression in NSCLC patients with brain metastases.
The Two-Sided Case
Upcoming Catalysts
- Potential NMPA approval decision for OPTUNE in pancreatic cancer (submission planned H2 2025, no confirmed date yet)
- Expansion of TTFields into additional solid tumor indications (NSCLC brain metastases via METIS trial data)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zai Lab Ltd 8-K ZLAB ·Originating report